BUZZ-AbbVie climbs on upbeat 2025 profit forecast

Updates

Shares of drugmaker AbbVie ABBV.N rise as much as 9.2% to a near three-month high of $191.77

*Stock set for its best day in over four years if gains hold

ABBV expects 2025 adj. profit of $12.12 to $12.32 per share, compared to analysts' average estimate of $12.18 per share

Raises 2027 combined sales forecast for newer immunology drugs Skyrizi and Rinvoq to more than $31 bln from $27 bln earlier

Company reports Q4 adj. profit of $2.16 per share, beating analysts' average est. of $2.12, according to data compiled by LSEG

ABBV stock rose 14.7% in 2024